VESPRIN
LOE ApproachingNDAORALTABLET
Approved
Sep 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESPRIN is an oral small-molecule tablet approved by NDA in 1957 and currently marketed by Bristol Myers Squibb. The specific indication and mechanism of action are not publicly documented in available data. This legacy product represents a historic entry in the pharmaceutical portfolio with over 65 years of clinical use.
LOE Approaching
Product is in late-stage lifecycle with modest competitive pressure (30/100), suggesting a maintenance-mode team focused on retention and transition planning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VESPRIN shows zero linked job openings, indicating limited hiring momentum and career growth potential on this product. Working on VESPRIN offers experience in legacy product stewardship and generic transition management, but limited exposure to innovation or market expansion.
Brand ManagerProduct Manager
Worked on VESPRIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.